You searched for "pharmaceuticals"
Part 2: Good news, bad news at the international conference
2 August 2024
| Peter Cackett
|
EYE - General
In the second instalment of this two-part article (click here for Part 1), our editor Peter Cackett presents the ‘good news’ and ‘bad news’ from an international conference experience. Readers will remember that in the last issue I left you...
The International Centre for Eye Health: weaving the global threads together
4 October 2023
| Marcia Zondervan, Hannah Faal, Covadonga Bascaran
|
EYE - General
The VISION 2020 LINKS & Networks Programme has been writing regular articles in Eye News about its capacity-strengthening activities in low- and middle-income countries (LMICs) for more than a decade. This, the first International Issue, is a landmark for Eye...
The past and the future for paediatric ophthalmology
1 June 2018
| Jane Ashworth, Chris Lloyd (Prof)
|
EYE - Paediatrics
The past 25 years have seen remarkable advances in clinical eye care for children in the UK. This has led to both improved outcomes and better patient and family experiences. There have been substantial changes to patient pathways, major advances...
Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice
1 February 2015
| Pearse A Keane (Prof), Adnan Tufail
|
EYE - Vitreo-Retinal
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...
A closer look at the new wave of glaucoma surgery – radical or old school?
1 October 2016
| Demetrios T Manasses, Leon Au
|
EYE - Glaucoma
Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...
Can coenzyme Q10 have a protective role in ethambutol-induced retinal ganglion cell toxicity
3 April 2023
| Claire Howard
|
EYE - Neuro-ophthalmology
|
Ethambutol, coenzyme Q10, ethambutol toxic optic neuropathy, retinal ganglion cells, tuberculosis
Tuberculosis (TB) is one of the most prevalent infectious diseases, especially in developing or low- income countries. Ethambutol is a widely used drug to treat TB. Ethambutol can cause visual disturbance including ethambutol toxic optic neuropathy (ETON). ETON is one...
A practical guide to anisocoria
Anisocoria means the presence of difference in the size of the right and left pupils. It is a sign of an abnormality in the efferent pathway. The first question facing the ophthalmologist is to ascertain if anisocoria is present or...Diabetes and diabetic retinopathy: Changes in understanding of the disease over the last 25 years and how the UK is helping low-income countries tackle the challenges
1 June 2018
| Marcia Zondervan, Covadonga Bascaran, Frank Sandi, Chloe Cornes, Pippa Williams
|
EYE - Vitreo-Retinal, EYE - General
Diabetes – a historical perspective Diabetes mellitus (DM) is a chronic disease caused by inherited and / or acquired deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin produced. Such a deficiency results in...
Insights on medical AI for ophthalmology: an update on current perspectives
3 June 2024
| Rod McNeil
|
EYE - General
Artificial intelligence (AI) has immense promise for revolutionising medical practice. Generative AI is a form of AI in which algorithms are trained on datasets that can be used to generate new content, such as text, images or video based on...
See sweet to C-suite: Imran Rahman
See also - See sweet to C-suite: Peter Holland In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part Two: David speaks...See sweet to C-suite: Carrie MacEwen
2 April 2025
| David Lockington
|
EYE - General
The business world tells us, “Know your why.” But increasingly, we live in a society where people think, “Why bother?” In this interview, David wants to know what makes Carrie MacEwen tick, and why she bothered to get involved locally,...
New study uncovers key mechanism behind a common genetic cause of age-related visual loss
19 September 2024
|
Cornea / External Eye Disease
|
endothelial cells, age, vision loss, research, academic, new, genetics, genome, Fuchs Endothelial Corneal Dystrophy, FECD
A groundbreaking study has revealed important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, providing hope for future therapeutic developments, and finding implications for other neurological diseases. FECD is a common,...